Esperion Therapeutics ESPR Non Cash Royalty Revenue Related To Sale Of Future Royalties
Non Cash Royalty Revenue Related To Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's non cash royalty revenue related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's non cash royalty revenue related to sale of future royalties?
- Esperion Therapeutics (ESPR) reported non cash royalty revenue related to sale of future royalties of $18.48M in Q1 2026.
- How has Esperion Therapeutics's non cash royalty revenue related to sale of future royalties changed year-over-year?
- Esperion Therapeutics's non cash royalty revenue related to sale of future royalties increased by 76.3% year-over-year, from $10.48M to $18.48M.
- What does non cash royalty revenue related to sale of future royalties mean?
- This represents the non-cash revenue recognized in the statement of cash flows resulting from the accounting treatment of future royalty sales. It reflects the amortization of deferred revenue associated with upfront payments received for the sale of future royalty streams. This metric is essential for understanding how accounting revenue recognition differs from actual cash receipts in royalty-based financing arrangements.